GPSM3

Summary

GPSM3 (G protein signaling modulator 3, HGNC:13945) is a protein-coding gene on chromosome 6p21.32, encoding G-protein-signaling modulator 3 (Q9Y4H4). Interacts with subunit of G(i) alpha proteins and regulates the activation of G(i) alpha proteins.

Predicted to enable GTPase regulator activity. Predicted to be involved in positive regulation of inflammatory response. Predicted to act upstream of or within positive regulation of cytokine production involved in inflammatory response and positive regulation of leukocyte chemotaxis. Predicted to be located in cytoplasm and plasma membrane.

Source: NCBI Gene 63940 — RefSeq curated summary.

At a glance

• GWAS associations: 33
• Clinical variants (ClinVar): 29 total
• MANE Select transcript: NM_001276501

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13945
Approved symbol	GPSM3
Name	G protein signaling modulator 3
Location	6p21.32
Locus type	gene with protein product
Status	Approved
Aliases	NG1, G18, G18.1a, G18.1b, G18.2, AGS4
Ensembl gene	ENSG00000213654
Ensembl biotype	protein_coding
OMIM	618558
Entrez	63940

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 nonsense_mediated_decay

ENST00000375040, ENST00000375043, ENST00000472768, ENST00000487761, ENST00000619085, ENST00000874270, ENST00000874271, ENST00000934374

RefSeq mRNA: 2 — MANE Select: NM_001276501 NM_001276501, NM_022107

CCDS: CCDS34419

Canonical transcript exons

ENST00000375040 — 4 exons

Exon	Start	End
ENSE00001660163	32192148	32192250
ENSE00001727499	32191709	32191908
ENSE00001811353	32192472	32192643
ENSE00003645792	32190766	32191503

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 99.44.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 48.9197 / max 2505.6758, expressed in 1578 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
72933	23.6894	1245
72936	13.0222	1334
72932	11.7123	752
72930	0.1925	93
72934	0.1237	58
72935	0.1138	54
72931	0.0657	20

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	99.44	gold quality
blood	UBERON:0000178	99.34	gold quality
spleen	UBERON:0002106	98.96	gold quality
lymph node	UBERON:0000029	98.55	gold quality
leukocyte	CL:0000738	98.52	gold quality
monocyte	CL:0000576	98.44	gold quality
vermiform appendix	UBERON:0001154	98.37	gold quality
bone marrow	UBERON:0002371	98.33	gold quality
bone marrow cell	CL:0002092	98.23	gold quality
right lung	UBERON:0002167	96.13	gold quality
upper lobe of left lung	UBERON:0008952	94.72	gold quality
placenta	UBERON:0001987	92.87	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.50	gold quality
lung	UBERON:0002048	91.95	gold quality
gall bladder	UBERON:0002110	91.89	gold quality
small intestine	UBERON:0002108	91.77	gold quality
omental fat pad	UBERON:0010414	90.78	gold quality
adipose tissue	UBERON:0001013	88.72	gold quality
right coronary artery	UBERON:0001625	88.05	gold quality
mucosa of transverse colon	UBERON:0004991	87.75	gold quality
duodenum	UBERON:0002114	87.71	gold quality
apex of heart	UBERON:0002098	87.27	gold quality
subcutaneous adipose tissue	UBERON:0002190	87.14	gold quality
tonsil	UBERON:0002372	86.55	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	86.51	gold quality
left uterine tube	UBERON:0001303	86.37	gold quality
rectum	UBERON:0001052	86.24	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	85.98	gold quality
transverse colon	UBERON:0001157	85.93	gold quality
intestine	UBERON:0000160	85.46	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-6701	yes	89.03
E-MTAB-10287	yes	32.88
E-HCAD-10	yes	26.98
E-GEOD-134144	yes	25.42
E-CURD-112	yes	19.13
E-MTAB-8410	yes	13.24
E-ANND-3	yes	11.73
E-MTAB-9388	yes	10.60
E-HCAD-8	no	175.97
E-CURD-89	no	96.31
E-MTAB-5061	no	3.84

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

46 targeting GPSM3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-143-3P	99.49	69.05	1457
HSA-MIR-4770	99.49	69.09	1451
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-6088	99.29	68.45	1284
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-3199	99.17	65.19	696
HSA-MIR-8052	99.17	65.01	719
HSA-MIR-6809-5P	99.13	68.45	1223
HSA-MIR-5001-5P	99.05	66.76	1972
HSA-MIR-6895-3P	98.79	65.69	996
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-6878-5P	98.49	67.91	2142
HSA-MIR-6824-3P	98.44	67.62	1154
HSA-MIR-6764-3P	98.44	67.64	1153

Literature-anchored findings (GeneRIF, showing 7)

• Mutational analysis of the role of GoLoco motifs in guanine nucleotide dissociation inhibitor activity of G18 protein. (PMID:14656218)
• AGS4-Galpha(i) complexes directly couple to a G-protein-coupled receptor and may serve as substrates for agonist-induced G-protein activation. (PMID:20452976)
• GPSM3 increases Gbeta stability until formation of the Gbetagamma dimer, including association of the Gbeta-GPSM3 complex with phosducin-like protein PhLP and T-complex protein 1 subunit eta (CCT7), two known chaperones of neosynthesized Gbeta subunits. (PMID:22167191)
• Phosphorylation of GPSM3 by a proline-directed serine/threonine kinase and the resultant association of 14-3-3 is the first description of post-translational regulation of GPSM3 subcellular localization (PMID:22843681)
• findings suggest that GPSM3 acts as a direct negative regulator of NLRP3 function. (PMID:25271165)
• Genetic variations in GPSM3 which are associated with protection from rheumatoid arthritis affect its transcript abundance. (PMID:26821282)
• role for GPSM3 in neutrophil migration toward proinflammatory chemoattractants LTB4 and CXCL8-a discovery that helps strengthen the association between the promoter-weakening GPSM3 SNP rs204989 and a reduced risk of rheumatoid arthritis (PMID:27307211)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
mus_musculus	Gpsm3	ENSMUSG00000034786

Paralogs (6): TTC28 (ENSG00000100154), GPSM2 (ENSG00000121957), TTC29 (ENSG00000137473), GPSM1 (ENSG00000160360), RAPSN (ENSG00000165917), TTC24 (ENSG00000187862)

Protein

Protein identifiers

G-protein-signaling modulator 3 — Q9Y4H4 (reviewed: Q9Y4H4)

Alternative names: Activator of G-protein signaling 4, G18.1b, Protein G18

All UniProt accessions (6): A0A024RCP6, E9PIE9, E9PIP3, P78548, Q9Y4H4, Q9Y4H5

UniProt curated annotations — full annotation on UniProt →

Function. Interacts with subunit of G(i) alpha proteins and regulates the activation of G(i) alpha proteins.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in heart, placenta, lung and liver.

Domain organisation. The GoLoco 1 and/or GoLoco 3 domains exhibit GDI activity towards GDP-bound G(i) alpha protein, but not the GoLoco 2 domain.

RefSeq proteins (2): NP_001263430, NP_071390 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003109	GoLoco_motif	Conserved_site
IPR011990	TPR-like_helical_dom_sf	Homologous_superfamily
IPR042888	GPSM3	Family

Pfam: PF02188

UniProt features (14 total): modified residue 5, domain 3, compositionally biased region 2, chain 1, mutagenesis site 1, sequence conflict 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y4H4-F1	71.77	0.24

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (5): 59, 62, 35, 39, 56

Mutagenesis-validated functional residues (1):

Position	Phenotype
121	restores g(i) alpha binding and gdi activity of the goloco 2 domain.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-418594	G alpha (i) signalling events

MSigDB gene sets: 240 (showing top): BROWNE_HCMV_INFECTION_30MIN_DN, GSE45365_NK_CELL_VS_CD11B_DC_DN, AP1_01, GOBP_CELL_CHEMOTAXIS, MODULE_255, GOBP_INFLAMMATORY_RESPONSE, GCM_MSN, MODULE_45, MODULE_317, LINDGREN_BLADDER_CANCER_CLUSTER_3_DN, GOBP_POSITIVE_REGULATION_OF_CYTOKINE_PRODUCTION, MODULE_16, GOBP_REGULATION_OF_LEUKOCYTE_MIGRATION, GOBP_LEUKOCYTE_CHEMOTAXIS, MODULE_118

GO Biological Process (4): positive regulation of leukocyte chemotaxis (GO:0002690), positive regulation of inflammatory response (GO:0050729), positive regulation of cytokine production involved in inflammatory response (GO:1900017), regulation of inflammatory response (GO:0050727)

GO Molecular Function (2): GTPase regulator activity (GO:0030695), protein binding (GO:0005515)

GO Cellular Component (3): cytoplasm (GO:0005737), plasma membrane (GO:0005886), cellular_component (GO:0005575)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
GPCR downstream signalling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
inflammatory response	2
positive regulation of leukocyte migration	1
regulation of leukocyte chemotaxis	1
leukocyte chemotaxis	1
positive regulation of chemotaxis	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
regulation of inflammatory response	1
positive regulation of cytokine production	1
cytokine production involved in inflammatory response	1
regulation of cytokine production involved in inflammatory response	1
regulation of defense response	1
regulation of response to external stimulus	1
GTPase activity	1
nucleoside-triphosphatase regulator activity	1
binding	1
intracellular anatomical structure	1
cellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

1490 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPSM3	EGFL8	Q99944	721
GPSM3	SUCLG2	Q96I99	718
GPSM3	PRRT1	Q99946	641
GPSM3	GPSM1	Q86YR5	599
GPSM3	PCP2	Q8IVA1	570
GPSM3	FGD2	Q7Z6J4	558
GPSM3	GPSM2	P81274	521
GPSM3	DXO	O77932	447
GPSM3	FKBPL	Q9UIM3	422
GPSM3	FBP1	P09467	419
GPSM3	FPR3	P25089	416
GPSM3	TDRD5	Q8NAT2	402
GPSM3	LYZ	P00695	394
GPSM3	TCF19	Q9Y242	381
GPSM3	PBX2	P40425	379

IntAct

184 interactions, top by confidence:

A	B	Type	Score
GPSM3	GNAI1	psi-mi:“MI:0915”(physical association)	0.830
GNAI1	GPSM3	psi-mi:“MI:0915”(physical association)	0.830
GPSM3	GNAI3	psi-mi:“MI:0915”(physical association)	0.780
GNAI3	GPSM3	psi-mi:“MI:0915”(physical association)	0.780
YWHAZ	GPSM3	psi-mi:“MI:0915”(physical association)	0.740
GNAI2	GPSM3	psi-mi:“MI:0915”(physical association)	0.670
GPSM3	GNAI2	psi-mi:“MI:0915”(physical association)	0.670
MEOX2	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
TADA2A	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
GPSM3	USHBP1	psi-mi:“MI:0915”(physical association)	0.560
GPSM3	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
GPSM3	TADA2A	psi-mi:“MI:0915”(physical association)	0.560
HSF2BP	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
TEX11	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
CTAG1A	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
FAM86C1P	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
IQCE	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
ZNF581	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
P4HA3	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
RIPK4	GPSM3	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (90): GPSM3 (Two-hybrid), GPSM3 (Two-hybrid), GPSM3 (Two-hybrid), GPSM3 (Two-hybrid), GPSM3 (Two-hybrid), USHBP1 (Two-hybrid), GPSM3 (Synthetic Growth Defect), GPSM3 (Two-hybrid), GPSM3 (Two-hybrid), GPSM3 (Affinity Capture-Western), GPSM3 (Reconstituted Complex), GPSM3 (Reconstituted Complex), GPSM3 (Two-hybrid), GPSM3 (Two-hybrid), GPSM3 (Two-hybrid)

ESM2 similar proteins: A7YY62, A7Z026, B2RYF1, H3BV60, O12972, O35393, O54951, O70141, O75078, O75864, P01344, P05524, P11487, P23695, P28686, P33717, P42642, P56717, Q00961, Q01098, Q02833, Q06643, Q06AS9, Q14957, Q15768, Q1LZB9, Q3SXP7, Q3U2I3, Q5R8V2, Q5TM22, Q6PCB0, Q862Z7, Q86VR8, Q8BKR5, Q8K4Q6, Q8N612, Q8TAD2, Q8WXS5, Q96FI4, Q96FT7

Diamond homologs: Q3U1Z5, Q6MG88, Q9Y4H4

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
GSK3A	“down-regulates quantity by destabilization”	GPSM3	phosphorylation
GPSM3	“down-regulates activity”	GNAI1	binding
14-3-3	“up-regulates quantity by stabilization”	GPSM3	binding
GPSM3	“down-regulates quantity by destabilization”	GNB1	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

29 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	2
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

490 predictions. Top by Δscore:

Variant	Effect	Δscore
6:32191703:TCTTA:T	donor_loss	0.9900
6:32191704:CTTA:C	donor_loss	0.9900
6:32191705:TTA:T	donor_loss	0.9900
6:32191706:TA:T	donor_loss	0.9900
6:32191707:ACCT:A	donor_loss	0.9900
6:32191708:C:CT	donor_loss	0.9900
6:32191850:C:CT	acceptor_gain	0.9900
6:32191866:TCAGT:T	acceptor_gain	0.9900
6:32191867:CAGTC:C	acceptor_gain	0.9900
6:32192703:T:TA	donor_gain	0.9900
6:32191504:C:CC	acceptor_gain	0.9800
6:32191707:A:AC	donor_gain	0.9800
6:32191708:C:CC	donor_gain	0.9800
6:32191867:CAGT:C	acceptor_gain	0.9800
6:32191871:C:CC	acceptor_gain	0.9800
6:32192468:TCA:T	donor_loss	0.9800
6:32192469:CACCT:C	donor_loss	0.9800
6:32192470:A:C	donor_loss	0.9800
6:32192471:C:A	donor_loss	0.9800
6:32191512:G:GC	acceptor_gain	0.9700
6:32191868:AGT:A	acceptor_gain	0.9700
6:32191868:AGTCT:A	acceptor_loss	0.9600
6:32191869:GT:G	acceptor_gain	0.9600
6:32191869:GTC:G	acceptor_loss	0.9600
6:32191870:TCTGC:T	acceptor_loss	0.9600
6:32191871:C:G	acceptor_loss	0.9600
6:32191872:T:A	acceptor_loss	0.9600
6:32192471:CCTG:C	donor_gain	0.9600
6:32192717:C:A	donor_gain	0.9600
6:32191873:G:C	acceptor_loss	0.9500

AlphaMissense

1003 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:32191722:A:G	I111T	0.996
6:32191722:A:T	I111N	0.995
6:32191722:A:C	I111S	0.992
6:32191824:A:G	L77P	0.989
6:32191433:A:T	L139Q	0.988
6:32191846:C:G	A70P	0.988
6:32191396:T:A	Q151H	0.987
6:32191396:T:G	Q151H	0.987
6:32191433:A:G	L139P	0.986
6:32191483:C:A	Q122H	0.986
6:32191483:C:G	Q122H	0.986
6:32191496:C:G	R118P	0.986
6:32191828:G:T	R76S	0.985
6:32191430:A:G	L140P	0.983
6:32191811:C:A	R81S	0.983
6:32191811:C:G	R81S	0.983
6:32191436:A:G	L138S	0.982
6:32191814:C:A	Q80H	0.981
6:32191814:C:G	Q80H	0.981
6:32191433:A:C	L139R	0.978
6:32191709:C:A	Q115H	0.978
6:32191709:C:G	Q115H	0.978
6:32191719:A:G	L112P	0.977
6:32191827:C:G	R76P	0.977
6:32191393:C:A	R152S	0.976
6:32191393:C:G	R152S	0.976
6:32191420:C:A	Q143H	0.976
6:32191420:C:G	Q143H	0.976
6:32191834:A:G	S74P	0.975
6:32191835:C:A	Q73H	0.975

dbSNP variants (sampled 300 via entrez): RS1000931193 (6:32194571 C>A), RS1001796081 (6:32190465 C>G,T), RS1001845749 (6:32196452 A>C,G), RS1002210751 (6:32190532 A>G), RS1002521536 (6:32196692 CTG>C), RS1003586041 (6:32191890 G>A), RS1003978412 (6:32194990 T>G), RS1004293066 (6:32192244 G>A,C), RS1004674647 (6:32190731 C>T), RS1005024340 (6:32190344 G>A), RS1005435146 (6:32196367 G>T), RS1005739658 (6:32193132 C>T), RS1007388429 (6:32195370 G>A,C), RS1007419485 (6:32194933 G>A), RS1009060447 (6:32196665 C>T)

Disease associations

OMIM: gene MIM:618558 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

33 associations (top):

Study	Trait	p-value
GCST001709_6	Atopic dermatitis	8.000000e-20
GCST001762_173	Obesity-related traits	1.000000e-06
GCST001942_21	Prostate cancer	5.000000e-09
GCST002737_5	Atopic dermatitis	3.000000e-07
GCST004131_25	Inflammatory bowel disease	2.000000e-31
GCST004133_79	Ulcerative colitis	5.000000e-65
GCST004521_10	Autism spectrum disorder or schizophrenia	2.000000e-13
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_118	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_13	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_154	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST004521_17	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_170	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_173	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_213	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_226	Autism spectrum disorder or schizophrenia	4.000000e-12
GCST004521_276	Autism spectrum disorder or schizophrenia	5.000000e-10
GCST004521_296	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_81	Autism spectrum disorder or schizophrenia	1.000000e-14
GCST005542_1	Sarcoidosis (non-Lofgren’s syndrome without extrapulmonary manifestations)	7.000000e-06
GCST008059_3	Estimated glomerular filtration rate	7.000000e-17
GCST008103_66	Bipolar disorder	7.000000e-07
GCST008916_27	Asthma	5.000000e-31
GCST009107_8	Body mass index variance	2.000000e-13
GCST009109_5	Hip circumference variance	5.000000e-11
GCST009121_10	Body mass index	9.000000e-15
GCST009123_7	Hip circumference	3.000000e-24

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004626	IGFBP-3 measurement
EFO:0004340	body mass index
EFO:0007789	BMI-adjusted waist circumference
EFO:0007788	BMI-adjusted waist-hip ratio

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	increases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
sulforaphane	decreases expression	1
sodium arsenite	increases expression	1
entinostat	increases expression	1
Bortezomib	decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic Trioxide	decreases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Diazinon	increases methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Smoke	increases expression	1
Testosterone	decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	increases expression	1
Antirheumatic Agents	decreases expression	1
tert-Butylhydroperoxide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.